furazolidone has been researched along with Cardiomyopathy, Dilated in 17 studies
Furazolidone: A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone acts by gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514)
furazolidone : A member of the class of oxazolidines that is 1,3-oxazolidin-2-one in which the hydrogen attached to the nitrogen is replaced by an N-{[(5-nitro-2-furyl)methylene]amino} group. It has antibacterial and antiprotozoal properties, and is used in the treatment of giardiasis and cholera.
Cardiomyopathy, Dilated: A form of CARDIAC MUSCLE disease that is characterized by ventricular dilation, VENTRICULAR DYSFUNCTION, and HEART FAILURE. Risk factors include SMOKING; ALCOHOL DRINKING; HYPERTENSION; INFECTION; PREGNANCY; and mutations in the LMNA gene encoding LAMIN TYPE A, a NUCLEAR LAMINA protein.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carteolol treatment increased beta-adrenergic receptor density, and the high carteolol dose restored SR Ca2+-ATPase and myofibrillar ATPase activities, along with creatine kinase, lactate dehydrogenase, aspartate transaminase, and ATP synthase activities, to normal." | 5.30 | Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol. ( Bristow, MR; DiSalvo, TG; Gwathmey, JK; Hajjar, RJ; Khan, F; Kim, CS; Matsumori, A, 1999) |
| "Carteolol treatment increased beta-adrenergic receptor density, and the high carteolol dose restored SR Ca2+-ATPase and myofibrillar ATPase activities, along with creatine kinase, lactate dehydrogenase, aspartate transaminase, and ATP synthase activities, to normal." | 1.30 | Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol. ( Bristow, MR; DiSalvo, TG; Gwathmey, JK; Hajjar, RJ; Khan, F; Kim, CS; Matsumori, A, 1999) |
| "(3) The two forms of dilated cardiomyopathy are associated with markedly disparate alterations in the concentration of polyunsaturated fatty acids in the triglyceride fraction of 1-2 month old turkey hearts." | 1.29 | Myocardial lipid composition in turkeys with dilated cardiomyopathy. ( Einzig, S; Holman, RT; Johnson, SB; Lax, D; Li, Y; Noren, GR; Staley, NA; Zhang, SL, 1994) |
| " We compared the effects of chronic administration of a beta 1-selective and a nonselective beta-receptor antagonist, an alpha-receptor antagonist, and two Ca2+ channel antagonists in the presence of Fz administration." | 1.29 | Differences in cardioprotective efficacy of adrenergic receptor antagonists and Ca2+ channel antagonists in an animal model of dilated cardiomyopathy. Effects on gross morphology, global cardiac function, and twitch force. ( Allen, PD; Apstein, CS; Chapados, R; Fuleihan, F; Glass, MG; Hajjar, RJ; Hamlin, R; Ingwall, JS; Liao, R; Lincoff, AM, 1993) |
| "In this model of dilated cardiomyopathy: (1) relaxation is markedly prolonged; (2) the response to beta adrenergic stimulation is diminished; (3) Mg-ATPase activities and myofibrillar protein content are reduced; and (4) sympathetic activity in the heart is markedly increased with depletion of noradrenaline stores." | 1.29 | Pathophysiological and biochemical characterisation of an avian model of dilated cardiomyopathy: comparison to findings in human dilated cardiomyopathy. ( Fuleihan, F; Glass, MG; Gwathmey, JK; Hajjar, RJ; Liao, R; Young, JB, 1993) |
| "These data indicate that congestive cardiomyopathy is associated with markedly increased permeability of sarcoplasmic reticulum to Ca and compensatorily increased Ca-ATPase activity." | 1.28 | Myocardial Ca-sequestration failure and compensatory increase in Ca-ATPase with congestive cardiomyopathy: kinetic characterization by a homogenate microassay using real-time ratiometric indo-1 spectrofluorometry. ( Julian, R; Mirsalimi, M; O'Brien, PJ; Shen, H; Weiler, J, 1991) |
| "In furazolidone-treated birds with resultant cardiac dilation there was myocyte hypertrophy, enlargement of nuclei and reorientation of subepicardial myocardial fibres." | 1.28 | Morphological changes associated with furazolidone-induced cardiomyopathy: effects of digoxin and propranolol. ( Gwathmey, JK, 1991) |
| "Free carnitine was elevated by 126% in left ventricle and by 54% in skeletal muscle of the furazolidone-treated turkeys (p less than 0." | 1.27 | Carnitine alterations in spontaneous and drug-induced turkey congestive cardiomyopathy. ( Borgwardt, B; Einzig, S; Judd, D; Noren, GR; Pierpont, ME; Staley, NA, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (23.53) | 18.7374 |
| 1990's | 10 (58.82) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (17.65) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, M | 2 |
| Wei, J | 2 |
| Shan, H | 2 |
| Wang, H | 1 |
| Zhu, Y | 1 |
| Xue, J | 1 |
| Lin, L | 2 |
| Yan, R | 2 |
| Zhang, R | 1 |
| Zhu, YH | 1 |
| Yu, Q | 1 |
| Fang, W | 1 |
| Zhu, N | 1 |
| Zheng, X | 1 |
| Na, R | 1 |
| Liu, B | 1 |
| Meng, L | 1 |
| Li, Z | 1 |
| Li, Q | 1 |
| Li, X | 1 |
| Lax, D | 2 |
| Holman, RT | 1 |
| Johnson, SB | 1 |
| Zhang, SL | 2 |
| Li, Y | 2 |
| Noren, GR | 3 |
| Staley, NA | 3 |
| Einzig, S | 3 |
| Glass, MG | 2 |
| Fuleihan, F | 2 |
| Liao, R | 3 |
| Lincoff, AM | 1 |
| Chapados, R | 1 |
| Hamlin, R | 1 |
| Apstein, CS | 1 |
| Allen, PD | 1 |
| Ingwall, JS | 2 |
| Hajjar, RJ | 3 |
| Young, JB | 1 |
| Gwathmey, JK | 6 |
| Nascimben, L | 1 |
| Friedrich, J | 1 |
| Genao, A | 1 |
| Seth, K | 1 |
| Schmidt, U | 1 |
| Carles, M | 1 |
| Kim, CS | 2 |
| Khan, F | 1 |
| DiSalvo, TG | 1 |
| Matsumori, A | 2 |
| Bristow, MR | 1 |
| Goldberg, L | 1 |
| Doye, AA | 1 |
| McCoy, Q | 1 |
| O'Brien, PJ | 2 |
| Shen, H | 1 |
| Weiler, J | 1 |
| Mirsalimi, M | 1 |
| Julian, R | 1 |
| Mirsalimi, SM | 1 |
| Qureshi, FS | 1 |
| Julian, RJ | 1 |
| Stroo, WE | 1 |
| Smith, HJ | 1 |
| Nuttall, A | 1 |
| Williams, L | 1 |
| Berry, JM | 1 |
| Elsperger, J | 1 |
| Pierpont, ME | 1 |
| Judd, D | 1 |
| Borgwardt, B | 1 |
17 other studies available for furazolidone and Cardiomyopathy, Dilated
| Article | Year |
|---|---|
Calreticulin-STAT3 signaling pathway modulates mitochondrial function in a rat model of furazolidone-induced dilated cardiomyopathy.
Topics: Animals; Animals, Newborn; Apoptosis; Blotting, Western; Calreticulin; Cardiomyopathy, Dilated; Cell | 2013 |
Suppression of PKCĪµ-mediated mitochondrial connexin 43 phosphorylation at serine 368 is involved in myocardial mitochondrial dysfunction in a rat model of dilated cardiomyopathy.
Topics: Administration, Oral; Animals; Cardiomyopathy, Dilated; Cells, Cultured; Connexin 43; Disease Models | 2015 |
Beneficial effects of intramyocardial mesenchymal stem cells and VEGF165 plasmid injection in rats with furazolidone induced dilated cardiomyopathy.
Topics: Animals; Cardiomyopathy, Dilated; Collagen; Flow Cytometry; Furazolidone; Heart Function Tests; Huma | 2015 |
Myocardial lipid composition in turkeys with dilated cardiomyopathy.
Topics: Aging; Animals; Arachidonic Acid; Cardiomyopathy, Dilated; Chromatography, Gas; Fatty Acids; Furazol | 1994 |
Differences in cardioprotective efficacy of adrenergic receptor antagonists and Ca2+ channel antagonists in an animal model of dilated cardiomyopathy. Effects on gross morphology, global cardiac function, and twitch force.
Topics: Animals; Calcium Channel Blockers; Cardiomyopathy, Dilated; Furazolidone; Heart; Heart Rate; In Vitr | 1993 |
Pathophysiological and biochemical characterisation of an avian model of dilated cardiomyopathy: comparison to findings in human dilated cardiomyopathy.
Topics: Adenosine Triphosphatases; Animals; Calcium; Cardiomyopathy, Dilated; Culture Techniques; Disease Mo | 1993 |
Decreased energy reserve in an animal model of dilated cardiomyopathy. Relationship to contractile performance.
Topics: Adenosine Triphosphate; Animals; Cardiomyopathy, Dilated; Creatine; Creatine Kinase; Disease Models, | 1996 |
Dilated cardiomyopathy in turkeys: an animal model for the study of human heart failure.
Topics: Actin Cytoskeleton; Adenylyl Cyclases; Animals; Calcium; Cardiomyopathy, Dilated; Disease Models, An | 1996 |
Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol.
Topics: Adenosine Triphosphate; Adenylyl Cyclases; Adrenergic beta-Antagonists; Animals; Blood Pressure; Bod | 1999 |
Effects of pranidipine, a calcium channel antagonist, in an avian model of heart failure.
Topics: Animals; Anti-Infective Agents, Local; Calcium; Calcium Channel Blockers; Cardiomyopathy, Dilated; D | 1999 |
Myocardial Ca-sequestration failure and compensatory increase in Ca-ATPase with congestive cardiomyopathy: kinetic characterization by a homogenate microassay using real-time ratiometric indo-1 spectrofluorometry.
Topics: Animals; Biological Transport, Active; Body Weight; Calcium; Calcium-Transporting ATPases; Cardiomyo | 1991 |
Morphological changes associated with furazolidone-induced cardiomyopathy: effects of digoxin and propranolol.
Topics: Animals; Cardiomyopathy, Dilated; Digoxin; Furazolidone; Heart; Propranolol; Turkeys | 1991 |
Myocardial biochemical changes in furazolidone-induced cardiomyopathy of turkeys.
Topics: Animals; Biological Transport; Calcium; Cardiomyopathy, Dilated; Cell Membrane Permeability; Creatin | 1990 |
A comparison of furazolidone and doxorubicin enhanced free radical chemistry.
Topics: Animals; Cardiomyopathy, Dilated; Cytochrome c Group; Doxorubicin; Epinephrine; Free Radicals; Furaz | 1988 |
Experimental models of heart failure.
Topics: Animals; Barbiturates; Blood Pressure; Blood Volume; Cardiomegaly; Cardiomyopathy, Dilated; Cats; Cr | 1985 |
Reduced lipid peroxidation in dilated hearts of cardiomyopathic turkeys.
Topics: Animals; Cardiomyopathy, Dilated; Furazolidone; In Vitro Techniques; Lipid Peroxidation; Lipid Perox | 1988 |
Carnitine alterations in spontaneous and drug-induced turkey congestive cardiomyopathy.
Topics: Animals; Cardiomyopathy, Dilated; Carnitine; Furazolidone; Heart Failure; Hemodynamics; Liver; Myoca | 1985 |